Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML
Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
Eltrombopag has been used in the treatment of immune thrombocytopenia (ITP), and
significantly increased platelet count and decreased fatal hemorrage. As it's known that all
patients with acute leukemia will experience bone marrow suppression and thrombocytopenia
after chemotherapy. Some patients even died of fatal bleeding during this period for lacking
of platelet transfusion or platelet transfusion refractoriness. So a lot needs to be done to
shortern thrombocytopenia time or reduce fatal hemorrage incidence after chemotherapy in
acute leukemia patients. In this prospective randomized controlled study, the effect and
safety of eltrombopag in the treatment of thrombocytopenia after consolidation therapy in
acute myeloid leukemia (AML) is evaluated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Dongguan Kanghua Hospital Guangzhou First People's Hospital Second Affiliated Hospital, Sun Yat-Sen University Southern Medical University, China Third Affiliated Hospital, Sun Yat-Sen University Wuhan General Hospital of Guangzhou Military Command